What SEC filings does Cardiff Oncology, Inc. submit to the SEC?

Cardiff Oncology, Inc. (CRDF) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CRDF?

A Form 4 for CRDF discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Cardiff Oncology, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CRDF?

The 10-K is Cardiff Oncology, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CRDF SEC filings directly on EDGAR?

You can view all historical Cardiff Oncology, Inc. filings on the SEC EDGAR company page for CRDF. Each filing card on this page links directly to the original SEC document.

How often does Cardiff Oncology, Inc. file with the SEC?

Cardiff Oncology, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CRDF shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CRDF SEC Filing News — Cardiff Oncology, Inc.

Latest SEC filings for Cardiff Oncology, Inc. (CRDF) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-14.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea…

Sector: Healthcare Industry: Biotechnology Market Cap: $70.3M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CRDF currently lean bullish. Of the 20 displayed SEC filing records, 4 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 10 insider transactions (Form 4) in this period.

CRDF Filing Activity Snapshot 2026-04-28 — 2026-09-14

Insider Transactions (Form 4)

4 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$1000.0K

PACE GARY W (Director) · 2026-07-16

687,285 shares · Form 4

Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Cardiff Oncology, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 6 compensation award and 4 open-market purchase. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×4: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Open-market purchase Insider Buying 2026-07-16

CRDF insider PACE GARY W (Director) bought 687,285 shares (~$1000.0K)

PACE GARY W, listed as Director at Cardiff Oncology, Inc., reported an open-market purchase of 687,285 CRDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	687,285	$1.46	$1000.0K
`P`	Open-market purchase derivative · Common Stock Purchase Warrant	687,285	—	—

Filing: Form 4 (Insider Transaction) Insider: PACE GARY W (Director) Shares: 687,285 Est. Value: $1000.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-07-16

CRDF insider Mohindru Mani (Director, Chief Executive Officer) bought 34,364 shares (~$50.0K)

Mohindru Mani, listed as Director, Chief Executive Officer at Cardiff Oncology, Inc., reported an open-market purchase of 34,364 CRDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	34,364	$1.46	$50.0K
`P`	Open-market purchase derivative · Common Stock Purchase Warrant	34,364	—	—

Filing: Form 4 (Insider Transaction) Insider: Mohindru Mani (Director, Chief Executive Officer) Shares: 34,364 Est. Value: $50.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-06-22

CRDF insider Mohindru Mani (Director, Chief Executive Officer) bought 24,703 shares (~$29.9K)

Mohindru Mani, listed as Director, Chief Executive Officer at Cardiff Oncology, Inc., reported an open-market purchase of 24,703 CRDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	24,703	$1.21	$29.9K

Filing: Form 4 (Insider Transaction) Insider: Mohindru Mani (Director, Chief Executive Officer) Shares: 24,703 Est. Value: $29.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-06-22

CRDF insider PACE GARY W (Director) bought 30,000 shares (~$36.6K)

PACE GARY W, listed as Director at Cardiff Oncology, Inc., reported an open-market purchase of 30,000 CRDF shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	30,000	$1.22	$36.6K

Filing: Form 4 (Insider Transaction) Insider: PACE GARY W (Director) Shares: 30,000 Est. Value: $36.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRDF insider Form 4 filed for equity award, exercise, or tax withholding

Armitage James O (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	40,565	—	—

Filing: Form 4 (Insider Transaction) Insider: Armitage James O (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRDF insider Form 4 filed for equity award, exercise, or tax withholding

White Lale (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	40,565	—	—

Filing: Form 4 (Insider Transaction) Insider: White Lale (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRDF insider Form 4 filed for equity award, exercise, or tax withholding

TANNENBAUM RENEE P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	40,565	—	—

Filing: Form 4 (Insider Transaction) Insider: TANNENBAUM RENEE P (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRDF insider Form 4 filed for equity award, exercise, or tax withholding

Markin Rodney S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	40,565	—	—

Filing: Form 4 (Insider Transaction) Insider: Markin Rodney S (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRDF insider Form 4 filed for equity award, exercise, or tax withholding

PACE GARY W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	40,565	—	—

Filing: Form 4 (Insider Transaction) Insider: PACE GARY W (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-28

CRDF insider Form 4 filed for equity award, exercise, or tax withholding

Aggarwal Ajay (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Options	400,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Aggarwal Ajay (Chief Operating Officer)

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Cardiff Oncology, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-14